Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available
2019
AbstractRuxolitinib was recently approved for the treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea based on data from the RESPONSE studies. This phase 3b, Ex...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
46
References
1
Citations
NaN
KQI